A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Discovery

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-16-0512PMID 27872130PMCID PMC5463454
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

  2014influential reference
• Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

  2014cited by this paper
• First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

  2014cited by this paper
• PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

  2014cited by this paper
• Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

  2014cited by this paper
• Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

  2014cited by this paper
• Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

  2013influential reference
• Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

  2013influential reference
• An ATP-Site On-Off Switch That Restricts Phosphatase Accessibility of Akt

  2012cited by this paper
• Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.

  2012cited by this paper
• First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

  2011influential reference
• Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

  2011cited by this paper
• Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis.

  2009cited by this paper
• Deregulation of the Akt pathway in human cancer.

  2008cited by this paper
• AKT signaling in regulating angiogenesis.

  2008cited by this paper
• AKT/PKB signaling: navigating downstream.

  2007cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

  1999cited by this paper
• Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

  1999cited by this paper
• Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

  1995cited by this paper

• Pharmacogenomic and in silico identification of isoform-selective AKT inhibitors from Pithecellobium dulce for precision cancer therapy.

  2026cites this paper
• The role and prospects of the Fudan classification in precision medicine for triple-negative breast cancer.

  2026cites this paper
• Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

  2026cites this paper
• The Potential of Phytochemicals to Overcome Multidrug Resistance in Metastatic Melanoma

  2025cites this paper
• Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies

  2025cites this paper
• AKT as a Therapeutic Target in Cancer.

  2025cites this paper
• PRKG1 hinders myogenic differentiation and predicts response to AKT inhibitor ipatasertib in Rhabdomyosarcoma

  2025cites this paper
• VIRMA-mediated SHQ1 m6A modification enhances liver regeneration through an HNRNPA2B1-dependent mechanism

  2025cites this paper
• Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients

  2025cites this paper
• The Link Between Endoplasmic Reticulum Stress and Lysosomal Dysfunction Under Oxidative Stress in Cancer Cells

  2025cites this paper
• Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy

  2025cites this paper
• Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K.

  2025cites this paper
• Targeting Akt Signaling Pathway in Cancer: Molecular Mechanisms and Advances in Therapeutic Interventions.

  2025cites this paper
• Small intestinal SMARCA4-deficient undifferentiated carcinoma with intussusception: A case report

  2025cites this paper
• Navigating the Complexity of PI3K/AKT Pathway in HER-2 Negative Breast Cancer: Biomarkers and Beyond.

  2024cites this paper
• A Phase I Study of the Pharmacokinetics and Safety of Ipatasertib, an Akt Inhibitor in Chinese Patients With Locally Advanced or Metastatic Solid Tumors.

  2024cites this paper
• Phosphatidic acid as a cofactor of mTORC1 in platinum-based chemoresistance: mechanisms and therapeutic potential.

  2024cites this paper
• AKT kinases as therapeutic targets

  2024cites this paper
• A Paradoxical AKT: Exploring the Promise and Challenges of PI3K/AKT/mTOR Targeted Therapies

  2024cites this paper
• The cellular signaling and regulatory role of protein phosphatase in tumor diagnosis: Upstream miRNAs of PTEN.

  2024cites this paper
• The treatment landscape of triple-negative breast cancer

  2024cites this paper
• Therapeutic Potential of Silver Nitroprusside Nanoparticles for Melanoma.

  2024cites this paper
• The essential roles of lncRNAs/PI3K/AKT axis in gastrointestinal tumors

  2024cites this paper
• Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer

  2024cites this paper
• Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.

  2024cites this paper
• Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma

  2023cites this paper
• Enzyme‐Responsive Branched Glycopolymer‐Based Nanoassembly for Co‐Delivery of Paclitaxel and Akt Inhibitor toward Synergistic Therapy of Gastric Cancer

  2023cites this paper
• A non‐canonical role of endothelin converting enzyme 1 (ECE1) in promoting lung cancer development via directly targeting protein kinase B (AKT)

  2023cites this paper
• Ipatasertib exhibits anti-tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo

  2023cites this paper
• PI3K signaling-regulated metabolic reprogramming: From mechanism to application.

  2023cites this paper
• Impact of AKT1 on cell invasion and radiosensitivity in a triple negative breast cancer cell line developing brain metastasis

  2023cites this paper
• Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

  2023cites this paper
• A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer.

  2023cites this paper
• Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article

  2023cites this paper
• CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma

  2023cites this paper
• Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis

  2023cites this paper
• Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type

  2023cites this paper
• Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

  2023cites this paper
• Emerging systemic treatment for metastatic castration-resistant prostate cancer: a review of recent randomized controlled trials

  2023cites this paper
• Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)

  2023cites this paper
• PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression

  2022cites this paper
• Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.

  2022cites this paper
• Research progress in protein microarrays: Focussing on cancer research

  2022cites this paper
• AKT Isoforms as a Target in Cancer and Immunotherapy.

  2022cites this paper
• Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer

  2022cites this paper
• Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications

  2022cites this paper
• A targeted genetic modifier screen in Drosophila uncovers vulnerabilities in a genetically complex model of colon cancer

  2022cites this paper
• Targeted Approaches in Metastatic Castration-Resistant Prostate Cancer: Which Data?

  2022cites this paper
• Identification of Lethal Inhibitors and Inhibitor Combinations for Mono-Driver versus Multi-Driver Triple-Negative Breast Cancer Cells

  2022cites this paper
• Studies on Biological and Molecular Effects of Small-Molecule Kinase Inhibitors on Human Glioblastoma Cells and Organotypic Brain Slices

  2022cites this paper
• Ipatasertib, an oral AKT inhibitor, inhibits cell proliferation and migration, and induces apoptosis in serous endometrial cancer.

  2022cites this paper
• Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy.

  2022cites this paper
• Discovery of Clinical Candidate NTQ1062 as a Potent and Bioavailable Akt Inhibitor for the Treatment of Human Tumors.

  2022cites this paper
• P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia

  2022cites this paper
• In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy

  2022cites this paper
• At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy

  2022cites this paper
• Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic

  2022cites this paper
• Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment

  2022cites this paper
• Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors

  2022cites this paper
• PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

  2022cites this paper
• AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?

  2021cites this paper
• A Crosstalk Between Dual-Specific Phosphatases and Dual-Specific Protein Kinases Can Be A Potential Therapeutic Target for Anti-cancer Therapy.

  2021cites this paper
• Retinal oxidative stress activates the NRF2/ARE pathway: An early endogenous protective response to ocular hypertension

  2021cites this paper
• Precision Oncology, Signaling and Anticancer Agents in Cancer Therapeutics.

  2021cites this paper
• Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers

  2021cites this paper
• Overview of recent advances in metastatic triple negative breast cancer

  2021cites this paper
• Antihypertrophic Memory After Regression of Exercise-Induced Physiological Myocardial Hypertrophy Is Mediated by the Long Noncoding RNA Mhrt779

  2021cites this paper
• Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity

  2021cites this paper
• Protein kinase inhibitors for the treatment of prostate cancer

  2021cites this paper
• Detecting Förster resonance energy transfer in living cells by conventional and spectral flow cytometry

  2021cites this paper
• Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

  2021cites this paper
• Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.

  2021cites this paper
• ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins

  2021cites this paper
• Akt phosphorylates insulin receptor substrate to limit PI3K-mediated PIP3 synthesis

  2021cites this paper
• Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

  2021cites this paper
• Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients

  2021cites this paper
• Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function

  2021cites this paper
• Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib

  2021cites this paper
• Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.

  2021cites this paper
• A SIMPLE ONE-POT SYNTHESIS OF PYRIMIDO[4,5-C]PYRIDAZINES AND IN SILICO STUDIES OF HUMAN AKT1 INHIBITORS

  2021cites this paper
• TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.

  2021cites this paper
• Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine

  2021cites this paper
• Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition

  2021cites this paper
• Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

  2021cites this paper
• An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT

  2021cites this paper
• Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

  2021cites this paper
• Platelet Proteomes, Pathways, and Phenotypes as Informants of Vascular Wellness and Disease.

  2021cites this paper
• Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer.

  2020cites this paper
• Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy

  2020cites this paper
• TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism

  2020cites this paper
• Inhibitors in AKTion: ATP-competitive vs allosteric

  2020cites this paper
• First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors

  2020cites this paper
• A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

  2020cites this paper
• Pyrazine ring-based Na+/H+ exchanger (NHE) inhibitors potently inhibit cancer cell growth in 3D culture, independent of NHE1

  2020cites this paper
• Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.

  2020cites this paper
• Molecular alterations and precision medicine in prostate cancer

  2020cites this paper
• Spotlight on AKT: Current Therapeutic Challenges.

  2020cites this paper
• Crosstalk between HSPA5 arginylation and sequential ubiquitination leads to AKT degradation through autophagy flux

  2020cites this paper
• Three-dimensional genome: developmental technologies and applications in precision medicine

  2020cites this paper
• Targeting AKT/PKB to improve treatment outcomes for solid tumors.

  2020cites this paper